Overlapping expression of serotonin transporters and neurokinin-1 receptors in posttraumatic stress disorder: A multi-tracer PET study

Molecular Psychiatry

Volumn 21, Issue 10, 2016, Pages 1400-1407

  Frick, A ^a   Ahs F ^a,b   Palmquist, A M ^a   Pissiota, A ^a   Wallenquist, U ^a   Fernandez, M ^a   Jonasson, M ^a   Appel, L ^a   Frans, O ^a   Lubberink, M ^a   Furmark, T ^a   Von Knorring, L ^a   Fredrikson, M ^a,b  

^a UPPSALA UNIVERSITY   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

3 AMINO 4 (2 DIMETHYLAMINOMETHYLPHENYLSULFANYL)BENZONITRILE C 11; GR 205171 C 11; NEUROKININ 1 RECEPTOR; SEROTONIN TRANSPORTER; TRACER; UNCLASSIFIED DRUG; 3-AMINO-4-(2-DIMETHYLAMINOMETHYLPHENYLSULFANYL)BENZONITRILE; ANILINE DERIVATIVE; PIPERIDINE DERIVATIVE; SEROTONIN; SUBSTANCE P; SULFIDE; TETRAZOLE DERIVATIVE; TRANSCRIPTOME; VOFOPITANT;

ADULT; AMYGDALA; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; INSULA; MALE; ORBITAL CORTEX; PATHOPHYSIOLOGY; PET SCANNER; PHYSICAL PARAMETERS; POSITRON EMISSION TOMOGRAPHY; POSTERIOR CINGULATE; POSTTRAUMATIC STRESS DISORDER; PRIMARY MOTOR CORTEX; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; PUTAMEN; REGION OF INTEREST; THALAMUS; ANXIETY DISORDER; BRAIN; BRAIN CORTEX; CASE CONTROL STUDY; GENETICS; METABOLISM; PROCEDURES; PSYCHOLOGY;

ADULT; AMYGDALA; ANILINE COMPOUNDS; ANXIETY DISORDERS; BRAIN; CASE-CONTROL STUDIES; CEREBRAL CORTEX; FEMALE; HUMANS; MALE; PIPERIDINES; POSITRON-EMISSION TOMOGRAPHY; RECEPTORS, NEUROKININ-1; SEROTONIN; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; STRESS DISORDERS, POST-TRAUMATIC; SUBSTANCE P; SULFIDES; TETRAZOLES; TRANSCRIPTOME;

EID: 84949057797     PISSN: 13594184     EISSN: 14765578     Source Type: Journal    
DOI: 10.1038/mp.2015.180     Document Type: Article

References (75)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th (edn). Text Revision American Psychiatric Publishing, Inc.: Washington, DC, USA, 2000.
2. Kessler RC, Petukhova M, Sampson NA, Zaslavsky AM, Wittchen H-U. Twelvemonth and lifetime prevalence and lifetime morbid risk of anxiety and mood disorders in the United States. Int J Methods Psychiatr Res 2012; 21: 169-184.
3. Perkonigg A, Pfister H, Stein MB, Höfler M, Lieb R, Maercker A et al. Longitudinal course of posttraumatic stress disorder and posttraumatic stress disorder symptoms in a community sample of adolescents and young Adults. AJP 2005; 162: 1320-1327.
4. Pietrzak RH, Goldstein RB, Southwick SM, Grant BF. Psychiatric comorbidity of full and partial posttraumatic stress disorder among older adults in the United States: results from wave 2 of the national epidemiologic survey on alcohol and related conditions. Am J Geriatr Psychiatry 2012; 20: 380-390.
5. Bailey CR, Cordell E, Sobin SM, Neumeister A. Recent progress in understanding the pathophysiology of post-traumatic stress disorder. CNS Drugs 2013; 27: 221-232.
6. Pitman RK, Rasmusson AM, Koenen KC, Shin LM, Orr SP, Gilbertson MW et al. Biological studies of post-traumatic stress disorder. Nat Rev Neurosci 2012; 13: 769-787.
7. Neumeister A, Normandin MD, Pietrzak RH, Piomelli D, Zheng MQ, Gujarro-Anton A et al. Elevated brain cannabinoid CB1 receptor availability in post-traumatic stress disorder: a positron emission tomography study. Mol Psychiatry 2013; 18: 1034-1040.
8. Pole N. The psychophysiology of posttraumatic stress disorder: a meta-analysis. Psychol Bull 2007; 133: 725-746.
9. Peri T, Ben-Shakhar G, Orr SP, Shalev AY. Psychophysiologic assessment of aver-sive conditioning in posttraumatic stress disorder. Biol Psychiatry 2000; 47: 512-519.
10. Sartory G, Cwik J, Knuppertz H, Schürholt B, Lebens M, Seitz RJ et al. In search of the trauma memory: a meta-analysis of functional neuroimaging studies of symptom provocation in posttraumatic stress disorder (PTSD). PLoS One 2013; 8: e58150.
11. Sehlmeyer C, Schöning S, Zwitserlood P, Pfleiderer B, Kircher T, Arolt V et al. Human fear conditioning and extinction in neuroimaging: a systematic review. PLoS One 2009; 4: e5865.
12. Rhodes RA, Murthy NV, Dresner MA, Selvaraj S, Stavrakakis N, Babar S et al. Human 5-HT transporter availability predicts amygdala reactivity in vivo. J Neurosci 2007; 27: 9233-9237.
13. Fisher PM, Meltzer CC, Ziolko SK, Price JC, Hariri AR. Capacity for 5-HT1A-medi-ated autoregulation predicts amygdala reactivity. Nat Neurosci 2006; 9: 1362-1363.
14. Åhs F, Frick A, Furmark T, Fredrikson M. Human serotonin transporter availability predicts fear conditioning. Int J Psychophysiol 2015; 10.1016/j.ijpsycho.2014. 12.002; e-pub ahead of print.
15. Murrough JW, Huang Y, Hu J, Henry S, Williams W, Gallezot J-D et al. Reduced amygdala serotonin transporter binding in posttraumatic stress disorder. Biol Psychiatry 2011; 70: 1033-1038.
16. Gressier F, Calati R, Balestri M, Marsano A, Alberti S, Antypa N et al. The 5-HTTLPR polymorphism and posttraumatic stress disorder: a meta-analysis. J Trauma Stress 2013; 26: 645-653.
17. Garpenstrand H, Annas P, Ekblom J, Oreland L, Fredrikson M. Human fear conditioning is related to dopaminergic and serotonergic biological markers. Behav Neurosci 2001; 115: 358-364.
18. Davidson JRT. Pharmacologic treatment of acute and chronic stress following trauma. J Clin Psychiatry 2006; 67: 34-39.
19. Burghardt NS, Sigurdsson T, Gorman JM, McEwen BS, LeDoux JE. Chronic anti-depressant treatment impairs the acquisition of fear extinction. Biol Psychiatry 2013; 73: 1078-1086.
20. Burghardt NS, Sullivan GM, McEwen BS, Gorman JM, LeDoux JE. The selective serotonin reuptake inhibitor citalopram increases fear after acute treatment but reduces fear with chronic treatment: a comparison with tianeptine. Biol Psychiatry 2004; 55: 1171-1178.
21. Houle S, Ginovart N, Hussey D, Meyer JH, Wilson AA. Imaging the serotonin transporter with positron emission tomography: initial human studies with [11C] DAPP and [11C]DASB. Eur J Nucl Med 2000; 27: 1719-1722.
22. Geracioti TD, Carpenter LL, Owens MJ, Baker DG, Ekhator NN, Horn PS et al. Elevated cerebrospinal fluid substance p concentrations in posttraumatic stress disorder and major depression. Am J Psychiatry 2006; 163: 637-643.
23. Mathew SJ, Vythilingam M, Murrough JW, Zarate CA Jr, Feder A, Luckenbaugh DA et al. A selective neurokinin-1 receptor antagonist in chronic PTSD: A randomized, double-blind, placebo-controlled, proof-of-concept trial. Eur Neuropsycho-pharmacol 2011; 21: 221-229.
24. Nakanishi S. Mammalian tachykinin receptors. Annu Rev Neurosci 1991; 14: 123-136.
25. Von Euler US, Gaddum JH. An unidentified depressor substance in certain tissue extracts. J Physiol 1931; 72: 74-87.
26. Ribeiro-da-Silva A, Hökfelt T. Neuroanatomical localisation of Substance P in the CNS and sensory neurons. Neuropeptides 2000; 34: 256-271.
27. Ebner K, Singewald N. The role of substance P in stress and anxiety responses. Amino Acids 2006; 31: 251-272.
28. Fujimura Y, Yasuno F, Farris A, Liow J-S, Geraci M, Drevets W et al. Decreased neurokinin-1 (substance P) receptor binding in patients with panic disorder: positron emission tomographic study with [18F]SPA-RQ. Biol Psychiatry 2009; 66: 94-97.
29. Michelgård Å, Appel L, Pissiota A, Frans Ö, Långström B, Bergström M et al. Symptom provocation in specific phobia affects the substance P neurokinin-1 receptor system. Biol Psychiatry 2007; 61: 1002-1006.
30. Ebner K, Rupniak NM, Saria A, Singewald N. Substance P in the medial amygdala: Emotional stress-sensitive release and modulation of anxiety-related behavior in rats. PNAS 2004; 101: 4280-4285.
31. Heldt SA, Davis M, Ratti E, Corsi M, Trist D, Ressler KJ. Anxiolytic-like effects of the neurokinin 1 receptor antagonist GR-205171 in the elevated plus-maze and contextual fear-potentiated startle model of anxiety in gerbils. Behav Pharmacol 2009; 20: 584-595.
32. Zhao Z, Yang Y, Walker DL, Davis M. Effects of substance P in the amygdala, ventromedial hypothalamus, and periaqueductal gray on fear-potentiated startle. Neuropsychopharmacology 2008; 34: 331-340.
33. Kwako LE, George DT, Schwandt ML, Spagnolo PA, Momenan R, Hommer DW et al. The neurokinin-1 receptor antagonist aprepitant in co-morbid alcohol dependence and posttraumatic stress disorder: a human experimental study. Psychopharmacology 2015; 232: 295-304.
34. Etkin A, Egner T, Kalisch R. Emotional processing in anterior cingulate and medial prefrontal cortex. Trends Cogn Sci 2011; 15: 85-93.
35. Motzkin JC, Philippi CL, Wolf RC, Baskaya MK, Koenigs M. Ventromedial prefrontal cortex is critical for the regulation of amygdala activity in humans. Biol Psychiatry 2015; 77: 276-284.
36. Etkin A, Wager TD. Functional neuroimaging of anxiety: a meta-analysis of emotional processing in PTSD, social anxiety disorder, and specific phobia. Am J Psychiatry 2007; 164: 1476-1488.
37. Bergström M, Fasth K-J, Kilpatrick G, Ward P, Cable KM, Wipperman MD et al. Brain uptake and receptor binding of two [11C]labelled selective high affinity NK1-antagonists, GR203040 and GR205171 - PET studies in rhesus monkey. Neuro-pharmacol 2000; 39: 664-670.
38. Sergeyev V, Hökfelt T, Hurd Y. Serotonin and substance P co-exist in dorsal raphe neurons of the human brain. Neuroreport 1999; 10: 3967-3970.
39. Hafizi S, Serres F, Pei Q, Totterdell S, Sharp T. Evidence for the differential co-localization of neurokinin-1 receptors with 5-HT receptor subtypes in rat forebrain. J Psychopharmacol 2012; 26: 505-515.
40. Shirayama Y, Mitsushio H, Takashima M, Ichikawa H, Takahashi K. Reduction of substance P after chronic antidepressants treatment in the striatum, substantia nigra and amygdala of the rat. Brain Res 1996; 739: 70-78.
41. Tuominen L, Nummenmaa L, Keltikangas-Järvinen L, Raitakari O, Hietala J. Mapping neurotransmitter networks with PET: An example on serotonin and opioid systems. Hum Brain Mapp 2014; 35: 1875-1884.
42. Blake DD, Weathers FW, Nagy LM, Kaloupek DG, Gusman FD, Charney DS et al. The development of a clinician-administered PTSD scale. J Trauma Stress 1995; 8: 75-90.
43. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. BJP 1979; 134: 382-389.
44. Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 1998; 59(Suppl 20): 22-33.
45. Logan J, Fowler JS, Volkow ND, Wang GJ, Ding YS, Alexoff DL. Distribution volume ratios without blood sampling from graphical analysis of PET data. J Cereb Blood Flow Metab 1996; 16: 834-840.
46. Ginovart N, Wilson AA, Meyer JH, Hussey D, Houle S. Positron emission tomography quantification of [11C]-DASB binding to the human serotonin transporter: modeling strategies. J Cereb Blood Flow Metab 2001; 21: 1342-1353.
47. Innis RB, Cunningham VJ, Delforge J, Fujita M, Gjedde A, Gunn RN et al. Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab 2007; 27: 1533-1539.
48. Patlak CS, Blasberg RG, Fenstermacher JD. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. J Cereb Blood Flow Metab 1983; 3: 1-7.
49. Meyer JH. Imaging the serotonin transporter during major depressive disorder and antidepressant treatment. J Psychiatry Neurosci 2007; 32: 86-102.
50. Tauscher J, Kielbasa W, Iyengar S, Vandenhende F, Peng X, Mozley D et al. Development of the 2nd generation neurokinin-1 receptor antagonist LY686017 for social anxiety disorder. Eur Neuropsychopharmacol 2010; 20: 80-87.
51. Hietala J, Nyman MJ, Eskola O, Laakso A, Grönroos T, Oikonen V et al. Visualization and quantification of neurokinin-1 (NK1) receptors in the human brain. Mol Imaging Biol 2005; 7: 262-272.
52. Svarer C, Madsen K, Hasselbalch SG, Pinborg LH, Haugbøl S, Frøkjaer VG et al. MR-based automatic delineation of volumes of interest in human brain PET images using probability maps. Neuroimage 2005; 24: 969-979.
53. Jonasson M. Automatic definition of volumes of interest using a probability template method (PVElab) without a structural MRI image. In: Poster presented at the 10th International Symposium on Functional Neuroreceptor Mapping of the Living Brain. Egmond aan Zee, the Netherlands 2014.
54. Murrough JW, Czermak C, Henry S, Nabulsi N, Gallezot J-D, Gueorguieva R et al. Theeffect of early trauma exposure on serotonin type 1B receptor expression revealed by reduced selective radioligand binding. Arch Gen Psychiatry 2011; 68: 892-900.
55. Shin LM, Liberzon I. The neurocircuitry of fear, stress, and anxiety disorders. Neuropsychopharmacology 2010; 35: 169-191.
56. Sullivan GM, Ogden RT, Huang Y, Oquendo MA, Mann JJ, Parsey RV. Higher in vivo serotonin-1A binding in posttraumatic strss disorder: A PET study with [11C] WAY-100635. Depress Anxiety 2013; 30: 197-206.
57. Maldjian JA, Laurienti PJ, Kraft RA, Burdette JH. An automated method for neuroanatomic and cytoarchitectonic atlas-based interrogation of fMRI data sets. Neuroimage 2003; 19: 1233-1239.
58. Jovanovic H, Lundberg J, Karlsson P, Cerin Å, Saijo T, Varrone A et al. Sex differences in the serotonin 1A receptor and serotonin transporter binding in the human brain measured by PET. NeuroImage 2008; 39: 1408-1419.
59. Engman J, Åhs F, Furmark T, Linnman C, Pissiota A, Appel L et al. Age, sex and NK1 receptors in the human brain - a positron emission tomography study with [11C]GR205171. Eur Neuropsychopharmacol 2012; 22: 562-568.
60. Nyman MJ, Eskola O, Kajander J, Vahlberg T, Sanabria S, Burns D et al. Gender and age affect NK1 receptors in the human brain - a positron emission tomography study with [18F]SPA-RQ. Int J Neuropsychopharmacol 2007; 10: 219-229.
61. Pietrzak RH, Gallezot J-D, Ding Y-S, Henry S, Potenza MN, Southwick SM et al. Association of posttraumatic stress disorder with reduced in vivo norepinephrine availability in the locus coeruleus. JAMA Psychiatry 2013; 70: 1199-1205.
62. Frick A, Åhs F, Engman J, Jonasson M, Alaie I, Björkstrand J et al. Serotoninsynthesis and reuptake in social anxiety disorder: a positron emission tomography study. JAMA Psychiatry 2015; 72: 794-802.
63. Näslund J, Studer E, Petterson R, Hagsäter M, Nilsson S, Nissbrandt H et al. Differences in anxiety-like behaviour within a batch of Wistar rats are associated with differences in serotonergic transmission, enhanced by acute SSRI administration and abolished by serotonin depletion. Int J Neuropsychopharmacol 2015; 18: pyv018.
64. Hwang BH, Katner J, Iyengar S. Corticotropin-releasing factor mRNA and substance P receptor binding in the paraventricular hypothalamic nucleus, central nucleus of the amygdala, and locus coeruleus of sprague-dawley rats following restraint-induced stress. J Mol Neurosci 2005; 25: 239-250.
65. Bassi GS, de Carvalho MC, Brandão ML. Effects of substance P and Sar-Met-SP, a NK1 agonist, in distinct amygdaloid nuclei on anxiety-like behavior in rats. Neu-rosci Lett 2014; 569: 121-125.
66. Truitt WA, Johnson PL, Dietrich AD, Fitz SD, Shekhar A. Anxiety-like behavior is modulated by a discrete subpopulation of interneurons in the basolateral amygdala. Neuroscience 2009; 160: 284-294.
67. Maubach KA, Martin K, Smith DW, Hewson L, Frankshun RA, Harrison T et al. Substance P stimulates inhibitory synaptic transmission in the guinea pig baso-lateral amygdala in vitro. Neuropharmacology 2001; 40: 806-817.
68. Morris MC, Compas BE, Garber J. Relationsamong posttraumatic stress disorder, comorbid major depression, and hpa function: a systematic review and meta-a-nalysis. Clin Psychol Rev 2012; 32: 301-315.
69. Jessop DS, Renshaw D, Larsen PJ, Chowdrey HS, Harbuz MS. Substance P is involved in terminating the hypothalamo-pituitary-adrenal axis response to acute stress through centrally located neurokinin-1 receptors. Stress 2000; 3: 209-220.
70. Frick A, Ahs F, Linnman C, Jonasson M, Appel L, Lubberink M et al. Increased neurokinin-1 receptor availability in the amygdala in social anxiety disorder: a positron emission tomography study with [11C]GR205171. Transl Psychiatry 2015; 5: e597.
71. Furmark T, Appel L, Michelgård Å, Wahlstedt K, Åhs F, Zancan S et al. Cerebral blood flow changes after treatment of social phobia with the neurokinin-1 antagonist GR205171, citalopram, or placebo. Biol Psychiatry 2005; 58: 132-142.
72. Kramer MS, Winokur A, Kelsey J, Preskorn SH, Rothschild AJ, Snavely D et al. Demonstration of the efficacy and safety of a novel substance P (NK1) receptor antagonist in major depression. Neuropsychopharmacology 2004; 29: 385-392.
73. Kramer MS, Cutler N, Feighner J, Shrivastava R, Carman J, Sramek JJ et al. Distinct mechanism for antidepressant activity by blockade of central substance P receptors. Science 1998; 281: 1640-1645.
74. Keller M, Montgomery S, Ball W, Morrison M, Snavely D, Liu G et al. Lack of efficacy of the substance p (neurokinin1 receptor) antagonist aprepitant in the treatment of major depressive disorder. Biol Psychiatry 2006; 59: 216-223.
75. Ratti E, Bellew K, Bettica P, Bryson H, Zamuner S, Archer G et al. Results from 2 randomized, double-blind, placebo-controlled studies of the novel NK1 receptor antagonist casopitant in patients with major depressive disorder. J Clin Psycho-pharmacol 2011; 31: 727-733.